Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angio Check Study of nivolumab for cutaneous angiosarcoma
jRCT2031200020Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in cutaneous angiosarcoma, sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate. Started May 2020; status: completed.
02
Drugs
03
Conditions
cutaneous angiosarcoma
Beyond the preview
Go deeper on jRCT2031200020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200020.